Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session 2: Gastrointestinal tumours

135MO - Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

Date

03 Dec 2023

Session

Mini oral session 2: Gastrointestinal tumours

Topics

Tumour Site

Gastric Cancer;  Gastro-Oesophageal Junction Cancer

Presenters

Yoon-Koo Kang

Citation

Annals of Oncology (2023) 34 (suppl_4): S1520-S1555. 10.1016/annonc/annonc1379

Authors

J.A. Ajani1, F. Lordick2, Y. Bang3, P.C. Enzinger4, D.H. Ilson5, M.A. Shah6, E. van Cutsem7, R. Xu8, G. Aprile9, J. Xu10, R.A. Pazo Cid11, Y. Kang12, J. Yang13, D. Moran14, P. Bhattacharya15, M. Matsangou16, A. Arozullah13, J.W. Park17, K. Shitara18

Author affiliations

  • 1 Department Of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 2 Department Of Medicine And University Cancer Center Leipzig, University of Leipzig Medical Center, Leipzig/DE
  • 3 Department Of Internal Medicine, Seoul National University College of Medicine, Seoul/KR
  • 4 Center For Esophageal And Gastric Cancer, Dana-Farber Cancer Institute, Boston/US
  • 5 Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 6 Medical Oncology & Hematology Department, Weill Cornell Medical College, New York/US
  • 7 Digestive Oncology, University Hospitals Gasthuisberg and KU Leuven, Leuven/BE
  • 8 Department Of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou/CN
  • 9 Department Of Oncology, Azienda ULSS 8 Berica, Vicenza/IT
  • 10 Department Of Gastrointestinal Oncology, The Fifth Medical Center of the PLA General Hospital, Beijing/CN
  • 11 Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza/ES
  • 12 Department Of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul/KR
  • 13 Clinical Development, Astellas Pharma Global Development, Inc., Northbrook/US
  • 14 Clinical Pharmacology And Exploratory Development Department, Astellas Pharma Global Development, Inc., Northbrook/US
  • 15 Oncology Clinical Operations, Astellas Pharma Global Development, Inc., Northbrook/US
  • 16 Oncology, Astellas Pharma Inc., Northbrook/US
  • 17 Data Science, Astellas Pharma Global Development, Inc., Northbrook/US
  • 18 Department Of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa/JP

Resources

This content is available to ESMO members and event participants.

Abstract 135MO

Background

The phase 3 SPOTLIGHT study showed statistically significant improvement with 1L zolbetuximab + a modified folinic acid, 5-FU, and oxaliplatin regimen (mFOLFOX6) vs placebo (PBO) + mFOLFOX6 in PFS (final; median 10.6 vs 8.7 mo, HR 0.75 [95% CI 0.60, 0.94], P = 0.0066) and OS (interim; median 18.2 vs 15.5 mo, HR 0.75 [95% CI 0.60, 0.94], P = 0.0053) in patients (pts) with CLDN18.2+, HER2−, LA unresectable or mG/GEJ adenocarcinoma. We present an updated efficacy and safety analysis with 9.7 mo additional follow-up from the primary analysis.

Methods

Pts were randomly assigned 1:1 to zolbetuximab IV 800 mg/m2 (cycle 1, day [D] 1) followed by 600 mg/m2 (every 3 weeks) + mFOLFOX6 IV (D1, 15, 29) for four 42-day cycles or to PBO + mFOLFOX6; pts without progressive disease (PD) continued with zolbetuximab or PBO, + folinic acid and 5-FU at investigator’s discretion, until PD or discontinuation criteria were met. Primary endpoint was PFS per RECIST v1.1 by IRC; OS was a key secondary endpoint.

Results

At data cutoff (June 29, 2023), 565 pts were assigned to zolbetuximab + mFOLFOX6 (n = 283) or PBO + mFOLFOX6 (n = 282). In zolbetuximab vs PBO arms, median follow-up was 17.9 vs 15.2 mo for PFS and 31.1 vs 29.6 mo for OS, respectively. Median PFS was 11.0 vs 8.9 mo (HR 0.73 [95% CI 0.59, 0.91], P = 0.0022). Median OS was 18.2 vs 15.6 mo (HR 0.78 [95% CI 0.64, 0.95], P = 0.0067), with follow-up ongoing until final analysis; 24-mo OS rate was 37.7% vs 29.1%. Most common TEAEs with zolbetuximab + mFOLFOX6 were nausea (zolbetuximab arm: 82.4% vs PBO arm: 61.5%), vomiting (67.4% vs 36.3%), and decreased appetite (48.7% vs 34.9%); incidences of serious TEAEs were similar between arms (47.0% vs 46.4%).

Conclusions

With longer follow-up, zolbetuximab + mFOLFOX6 continued to demonstrate statistically significant improvement in PFS and OS compared with PBO + mFOLFOX6, with no new safety signals—supporting zolbetuximab + mFOLFOX6 as a potential new option for 1L treatment of pts with CLDN18.2+, HER2–, LA unresectable or mG/GEJ adenocarcinoma.

Clinical trial identification

NCT03504397.

Editorial acknowledgement

Medical writing support, conducted in accordance with Good Publication Practice (GPP 2022) and the International Committee of Medical Journal Editors (ICMJE) guidelines, was provided by Ann Ferguson, PhD, of Oxford PharmaGenesis Inc.

Legal entity responsible for the study

Astellas Pharma Inc.

Funding

Astellas Pharma Inc.

Disclosure

J.A. Ajani: Financial Interests, Personal, Research Funding: Astellas Pharma Inc., Bristol Myers Squibb, Merck & Co., Zymeworks, Taiho Pharmaceutical, Delta-Fly Pharma, Inc., ProLynx Inc, Daiichi Sankyo, Leap Therapeutics, Inc., Turning Point Therapeutics, Inc., Lanova Pharma, and Gilead Sciences, Inc; Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Merck & Co., Astellas Pharma Inc., Taiho Pharmaceutical, Zymeworks, BeiGene, AstraZeneca, Amgen, Novartis, Gilead Sciences, Inc., Servier Laboratories, Arcus Biosciences, and GRAIL; Financial Interests, Personal, Other, travel: Daiichi Sankyo, Bristol Myers Squibb, Aadi Bioscience, and Merck & Co. F. Lordick: Financial Interests, Personal, Advisory Board: Amgen, Astellas, BMS, Bayer, BeiGene, Biontech, Eli Lilly, Elsevier, MSD, Novartis, Roche, Daiichi Sankyo, PAGE; Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Eli Lilly, Imedex, Incyte, MSD, MedUpdate, Medscape, Merck Serono, Roche, Servier, StreamedUp!, Daiichi Sankyo, Novartis, Art Tempi; Financial Interests, Personal, Writing Engagement: Deutscher Ärzteverlag, Iomedico, Springer-Nature; Financial Interests, Institutional, Research Grant: BMS, Gilead. Y. Bang: Financial Interests, Personal, Research Funding: Astellas Pharma Inc., Genentech, Roche Holding AG, Merck Serono, Daiichi Sankyo, MSD, Amgen, and BeiGene; Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, Daiichi Sankyo, ALX Oncology, Hanmi Pharmaceutical, Merck Serono, Astellas Pharma Inc., Samyang Biopharm Corporation, and Daewoong Pharmaceutical. P.C. Enzinger: Financial Interests, Personal, Research Funding: Astellas Pharma Inc.; Financial Interests, Personal, Speaker, Consultant, Advisor: ALX Oncology, Arcus Biosciences, Astellas Pharma Inc., AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Chimeric Therapeutics, Celgene, Coherus BioSciences, Daiichi Sankyo, Five Prime Therapeutics, Inc., IDEAYA Biosciences, Istari Oncology, Legend. D.H. Ilson: Financial Interests, Personal, Research Funding: Astellas Pharma Inc.; Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, Bayer, Astellas Pharma Inc., Merck & Co., Daiichi Sankyo, Natera Inc, Taiho Pharmaceutical, Bristol Myers Squibb, Eli Lilly and Company, Roche Holding AG, and AstraZeneca; Financial Interests, Personal, Advisory Board: MacroGenics, and Merck & Co. M.A. Shah: Financial Interests, Personal, Research Funding: Astellas Pharma Inc., Merck & Co., Bristol Myers Squibb, and Oncolys BioPharma; Financial Interests, Personal, Leadership Role: ASCO Leadership Council. E. van Cutsem: Financial Interests, Personal, Advisory Board: AbbVie, ALX, Amgen, Array, Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, GSK, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seattle Genetics, Servier, Takeda, Terumo, Taiho, Zymeworks; Financial Interests, Institutional, Research Grant: Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier. R. Xu: Financial Interests, Personal, Invited Speaker: BMS, MSD; Financial Interests, Personal, Advisory Board: Henrui, BeiGene, Astellas, Merck, Junshi. G. Aprile: Financial Interests, Personal, Research Funding: Astellas Pharma Inc.; Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, AstraZeneca, Bristol Myers Squibb, Merck & Co., MSD, and Novartis; Financial Interests, Personal, Financially compensated role: Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, Merck & Co., MSD, and Novartis. J. Xu: Financial Interests, Personal, Research Funding: Astellas Pharma Inc. R.A. Pazo Cid: Financial Interests, Personal, Advisory Board: Roche, BMS, Servier, Ipsen, Lilly, AstraZeneca; Financial Interests, Personal, Invited Speaker: Servier, BMS, Roche, Eisai; Financial Interests, Personal and Institutional, Local PI, Support for manuscript presentation (funding, provision of study materials, medical writing, article processing charges): Ipsen, Astellas. Y. Kang: Financial Interests, Personal, Advisory Board: ALX Oncology, Zymeworks, Amgen, Novartis, Macrogenics, Daehwa, Blueprint, Surface Oncology, BMS, Merck, Roche, Liscure. J. Yang: Financial Interests, Personal, Full or part-time Employment: Astellas Pharma Inc. D. Moran, P. Bhattachary: Financial Interests, Personal, Full or part-time Employment: Astellas Pharma Inc. M. Matsangou: Financial Interests, Personal, Full or part-time Employment: Astellas Pharma Global Development, Inc. A. Arozullah: Financial Interests, Personal, Full or part-time Employment: Astellas Pharma Inc.; Financial Interests, Personal, Stocks/Shares: Astellas Pharma Inc. J.W. Park: Financial Interests, Personal, Full or part-time Employment: Astellas Pharma Inc. K. Shitara: Financial Interests, Personal, Advisory Board: Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono, MSD, Taiho, Novartis, AbbVie, GSK, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Guardant Health Japan Corp, Astellas Pharma Inc.; Financial Interests, Personal, Invited Speaker: Janssen Pharmaceutical K.K.; Financial Interests, Institutional, Research Grant: Astellas, Ono, Daiichi Sankyo, Taiho, Chugai, MSD, Eisai, Amgen.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.